At close: December 20 at 4:00:00 PM EST
After hours: December 20 at 7:52:51 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
743.0000
743.0000
810.0000
853.0000
763.0000
Operating Expense
8,938.0000
8,938.0000
10,906.0000
13,695.0000
14,902.0000
Operating Income
-8,195.0000
-8,195.0000
-10,096.0000
-12,842.0000
-14,139.0000
Net Non Operating Interest Income Expense
492.0000
492.0000
206.0000
6.0000
-342.0000
Other Income Expense
69.0000
69.0000
-283.0000
221.0000
38.0000
Pretax Income
-7,634.0000
-7,634.0000
-10,173.0000
-12,615.0000
-14,443.0000
Net Income Common Stockholders
-7,634.0000
-7,634.0000
-10,173.0000
-15,205.0000
-15,158.0000
Diluted NI Available to Com Stockholders
-7,634.0000
-7,634.0000
-10,173.0000
-15,205.0000
-15,158.0000
Basic EPS
-3.00
--
-3.00
-9.00
-12.00
Diluted EPS
-3.00
--
-3.00
-9.00
-12.00
Basic Average Shares
4,261.1130
--
2,719.1540
1,843.5990
1,194.7040
Diluted Average Shares
4,261.1130
--
2,719.1540
1,843.5990
1,194.7040
Total Operating Income as Reported
-8,195.0000
-8,195.0000
-10,096.0000
-12,842.0000
-14,139.0000
Total Expenses
8,938.0000
8,938.0000
10,906.0000
13,695.0000
14,902.0000
Net Income from Continuing & Discontinued Operation
-7,634.0000
-7,634.0000
-10,173.0000
-12,615.0000
-14,443.0000
Normalized Income
-7,703.0000
-7,703.0000
-9,890.0000
-12,836.0000
-14,481.0000
Interest Income
506.0000
506.0000
222.0000
24.0000
44.0000
Interest Expense
--
--
--
--
363.0000
Net Interest Income
492.0000
492.0000
206.0000
6.0000
-342.0000
EBIT
-8,195.0000
-8,195.0000
-10,096.0000
-12,842.0000
-14,139.0000
EBITDA
-8,180.0000
-8,180.0000
-10,082.0000
-12,828.0000
-14,127.0000
Reconciled Depreciation
15.0000
15.0000
14.0000
14.0000
12.0000
Net Income from Continuing Operation Net Minority Interest
-7,634.0000
-7,634.0000
-10,173.0000
-12,615.0000
-14,443.0000
Total Unusual Items Excluding Goodwill
69.0000
69.0000
-283.0000
221.0000
38.0000
Total Unusual Items
69.0000
69.0000
-283.0000
221.0000
38.0000
Normalized EBITDA
-8,249.0000
-8,249.0000
-9,799.0000
-13,049.0000
-14,165.0000
12/31/2020 - 11/6/2012
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
BLRX BioLineRx Ltd.
0.2030
+0.50%
ENLV Enlivex Therapeutics Ltd.
1.2400
+5.08%
UNCY Unicycive Therapeutics, Inc.
0.6840
-3.66%
XTLB XTL Biopharmaceuticals Ltd.
1.4400
0.00%
APVO Aptevo Therapeutics Inc.
4.4100
-2.65%
PLUR Pluri Inc.
4.8200
+5.93%
EVGN Evogene Ltd.
1.3500
+4.65%
SXTP 60 Degrees Pharmaceuticals, Inc.
1.2600
-10.64%
PPBT Purple Biotech Ltd
3.4200
-0.87%
PLX Protalix BioTherapeutics, Inc.
1.7600
+1.15%